DEVON, Pa., Nov. 21, 2016 — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that Armando Anido, Chairman and CEO, and other members of Company management will participate at various upcoming investor meetings and conferences in November, including:
- Oppenheimer Life Sciences Summit in New York City on November 29, 2016
- 28th Annual Piper Jaffray Healthcare Conference in New York City on November 30, 2016
- Company presentation is at 2:30 pm ET
To listen to a webcast of the Piper presentation live, please visit the Investor Relations page of www.zynerba.com. A replay of the webcast will be available for 90 days following the conclusion of the respective event.
About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) is a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for